Positive Outlook for Kura Oncology: Buy Rating Supported by Promising Clinical Results and Strategic Advancements

Kura Oncology (KURA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $40.00 price target.

Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Kura Oncology’s recent clinical trial results and strategic positioning. The Phase 2 KOMET-001 study demonstrated promising outcomes for ziftomenib, particularly in patients with NPM1-mutant relapsed/refractory acute myeloid leukemia (AML), achieving a statistically significant primary endpoint of complete remission with full or partial hematologic recovery. The treatment showed consistent response rates regardless of prior venetoclax exposure and maintained a favorable safety profile, with minimal treatment-related adverse events leading to discontinuation.
Furthermore, Kura Oncology is advancing towards regulatory milestones, having submitted a New Drug Application (NDA) for ziftomenib, with expectations of Priority Review acceptance in the second quarter of 2025. The company is actively preparing for a potential commercial launch, indicating strong commercial readiness. These factors collectively suggest a positive outlook for Kura Oncology, supporting the Buy rating by Joseph Pantginis.

In another report released today, Barclays also maintained a Buy rating on the stock with a $11.00 price target.